Advanced search
Publication Cover
Journal of Asthma Volume 54, 2017 - Issue 3
Submit an article Journal homepage
1,051
Views
25
CrossRef citations to date
0
Altmetric
Pharmcotherapy

The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis

Jinfeng LiDepartment of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China
, MD,
Fangfang WangDepartment of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, ChinaCorrespondence[email protected]
, MD,
Cunzhi LinDepartment of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China
, MD,
Jianxin DuDepartment of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China
, MD,
Baohong XiaoDepartment of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China
, MD,
Chunhua DuDepartment of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China
, MD &
Jiaxing SunDepartment of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China
, MD show all
Pages 300-307 | Received 29 May 2016, Accepted 10 Jul 2016, Published online: 27 Oct 2016

References

  • Global Initiative for Asthma. (GINA report) Global Stragegy for Asthma Management and Prevention; 2014.
  • Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178(3):218–24.
  • Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323(15):1033–9.
  • Nissim Ben Efraim AH, Levi-Schaffer F. Tissue remodeling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis 2008;2:163–71.
  • Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013;132(4):821–7.
  • Zeiger RS, Schatz M, Li Q, Chen W, Khatry DB, Gossage D, et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract 2014;2(6):741–50.
  • Custovic A, Johnston SL, Pavord I, Gaga M, Fabbri L, Bel EH, et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy 2013;68:1520–31.
  • Takatsu K, Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol 2008;20(3):288–94.
  • Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014;2(11):879–90.
  • Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371(13):1198–207.
  • Markham A. Reslizumab: First Global Approval. Drugs. 2016, 76(8):907–911.
  • Jadad AR. Randomised controlled trials. London: BMJ Publishing Group; 1998.
  • Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, v.5.1 [updated March 2011]. Cochrane Collaboration Web site. http://www.cochrane-handbook.org/.
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
  • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
  • Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3(5):355–66.
  • Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184(10):1125–32.
  • Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. in press.
  • Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: A randomized phase 3 study. Chest. in press.
  • Lim HF, Nair P. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma. Expert Rev Respir Med 2015;9(2):135–42.
  • Zhang J, Kuvelkar R, Murgolo NJ, Taremi SS, Chou CC, Wang P, et al. Mapping and characterization of the epitope (s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol 1999;11:1935–44.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.